NCT07491367 Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems
| NCT ID | NCT07491367 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Knee Osteoarthristis |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 20 participants in total. It began in 2026-09-01 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.
Eligibility Criteria
Inclusion Criteria: * Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis * Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee * Will be able to attend and perform physical therapy Exclusion Criteria: * Received injection therapy for knee osteoarthritis in the past 6 months * Have severe arthritis diagnosed in ≥1 major joint by radiology criteria * History of septic arthritis * Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery) * Have had high tibial osteotomy, partial knee replacement, patellar resurfacing, total knee replacement, or have existing surgical hardware in the knee * Received a platelet-rich plasma injection elsewhere in the body within the past 3 months * Have a platelet disorder or bleeding disorder * Have a rheumatologic disease, autoimmune disorder, immunocompromised status, or active history of cancer * Are taking chemotherapy, require regular prednisone, or require regular anti-inflammatory use * Are pregnant, breastfeeding, or unwilling to practice birth control during the study * If both knees have osteoarthritis and the other knee has KL score equal to or greater than 2. * Have uncontrolled illness, physical disability, or other contraindication to aerobic exercise training
Contact & Investigator
Anthony Luke, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07491367 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Knee Osteoarthristis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07491367 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07491367 currently recruiting?
Yes, NCT07491367 is actively recruiting participants. Contact the research team at joel.kopcow@ucsf.edu for enrollment information.
Where is the NCT07491367 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07491367 clinical trial?
NCT07491367 is sponsored by University of California, San Francisco. The principal investigator is Anthony Luke, MD at University of California, San Francisco. The trial plans to enroll 20 participants.